Genexine Advances DNA Vaccine With Mid-Stage Cervical Cancer Success
In Regimen With Keytruda
The Korean firm’s DNA vaccine has shown promise in a Phase II cervical cancer trial in combination with Merck’s Keytruda, prompting the firm to tout potential in the difficult PD-1 negative group.
You may also be interested in...
Genexine is set to progress and expand this year the clinical development of its leading assets, orphan disease drugs and cancer immunotherapies. The South Korean biotech company's CEO talks in an interview with PharmAsia News about its R&D and business strategies, as well as the challenges faced by the wider Korean biotech industry.
Recent executive changes in the industry include C-suite changes at Solid Biosciences and Merck & Co. Meanwhile, new directors were appointed at Allergy Therapeutics and Synairgen.
The US firm’s adagrasib regimen has failed to differentiate itself from Keytruda plus chemotherapy in two early mNSCLC trials but Mirati is nonetheless forging ahead with pivotal development, albeit with strictly defined populations.